The objective of this study was to assess the intraocular pressure (IOP) as well as the anatomical modifications of the anterior segment following an aflibercept injection. Patients underwent an aflibercept intravitreal injection (IVI) (0.05 ml) with a 30.5-gauge needle and an antireflux system. IOP was assessed before injection (T0), immediately after (T1), and 5 min (T5), 15 min (T15), and 45 min (T45) after the IVI. Before the IVI and immediately after the T1 measurement, a PENTACAM® acquisition was used to evaluate the anterior chamber parameters (anterior chamber volume, depth and measure of the iridocorneal angle). At T0, IOP was 12.9 ± 1.3 mm Hg. IOP significantly increased after IVI (42.7 ± 3 mm Hg, p < 0.001). IOP returned to baseline at T45 (13.0 ± 1.2 mm Hg, p = 0.877). Anterior chamber volume decreased after IVI (160.6 vs. 168.3 mm3, p = 0.002). No significant changes were found for iridocorneal angle and anterior chamber depth. Aflibercept IVI causes an acute increase in IOP over a short period without iridocorneal angle closure.

Singh RSJ, Kim JE: Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drugs Aging 2012;29:949-956.
El Chehab H, Le Corre A, Agard E, Ract-Madoux G, Coste O, Dot C: Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol 2013;23:277-283.
Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S: Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol (Copenh) 2011;89:138-142.
Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE, et al: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology 2012;119:1388-1398.
Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-1203.
El Chehab H, Le Corre A, Giraud J-M, Ract-Madoux G, Swalduz B, Dot C: Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections. J Fr Ophtalmol 2012;35:614-621.
Lemos-Reis R, Moreira-Gonçalves N, Melo AB, Carneiro AM, Falcão-Reis FM: Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clin Ophthalmol 2014;8:1383-1388.
Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I: Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85:777-781.
Pang CE, Mrejen S, Hoang QV, Sorenson JA, Freund KB: Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina 2015;35:1401-1406.
Lemos V, Cabugueira A, Noronha M, Abegão Pinto L, Reina M, Branco J, et al: Intraocular pressure in eyes receiving intravitreal antivascular endothelial growth factor injections. Ophthalmologica 2015;233:162-168.
Carnota-Méndez P, Méndez-Vázquez C, Otero-Villar J, Saavedra-Pazos JA: Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol 2014;24:771-777.
Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P: Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658-661.
Farhood QK, Twfeeq SM: Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. Clin Ophthalmol 2014;8:599-604.
Demirel S, Batioğlu F, Özmert E, Erenler F: The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res 2015;40:87-92.
Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-142.
Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, et al: Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-1635.
Agard E, Elchehab H, Ract-Madoux G, Russo A, Lagenaite C, Dot C: Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol 2015;50:127-131.
Carlson KH, McLaren JW, Topper JE, Brubaker RF: Effect of body position on intraocular pressure and aqueous flow. Invest Ophthalmol Vis Sci 1987;28:1346-1352.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.